Presentation

Implantica is a MedTech company dedicated to bringing advanced medical implants into the body. The company completed listing on Nasdaq First North Premier Growth Market in Q3 of 2020. Implantica’s first product, RefluxStop™, will potentially create a paradigm shift in anti-reflux surgery as supported by the successful clinical trial results. Implantica’s Wireless Energizing Platform, developed for eHealth Smart Medical Implants (prototype not yet CE marked), is designed to make previously inconceivable medical implants possible with the ability to power remote controlled implants wirelessly through intact skin. The company is developing two active implants in urinary incontinence and obesity – UriControl® and AppetiteControl™, which are both utilising the Wireless Energizing Platform. e-InVivo™ is designed to monitor a broad range of health parameters and provide diagnostic information with early detection of diseases as well as control treatment from inside the body. Implantica was founded in 2015 and is based in Switzerland.

Recent highlights
In Q1, net sales amounted to EUR 198k (82), corresponding to a 141% growth y/y. Adjusted gross margin increased to 95% (91). Moreover, did Implantica complete the RefluxStop™ EU MDR technical documentation submission, and performed a successful first RefluxStop™ procedure in the UK. Also, preparations for an extensive RefluxStop™ PMA application for FDA approval and expansions of the US subsidiary, Implantica Inc made. Implantica submited an extensive patent filing that encompasses 59 new patent applications, mainly focused on the eHealth platform.

Outlook
Implantica has announced it will continue to focus on the commercialization of RefluxStop™ in which it sees great potential. The product has had good test results and has a competitive edge over competitors as it does not compress the food passageway. The most urgent matter is the preparation of the PMA application for the FDA, however, no further details of the expected time for submission have been released. Factset consensus, estimate sales and EBIT to reach SEK 19.3m and SEK -238m by the end of 2022.